PLoS ONE · 2020 · 29 citations · 42 references
MedicineCardiologyHematologyClinical CardiologyHemostasisTransfusion MedicineCardiac BiomarkersHeart FailurePlatelet ActivationPlatelet AggregationPlatelet FunctionPlatelet PhysiologyB-type Natriuretic PeptidesHeart Failure BiomarkersHeart Failure EpidemiologyKaplan-meier Survival EstimatesPlatelet Activation AssaysPrognostic PredictionPrognostic Variables
BACKGROUND: The prognostic impact of platelet distribution width (PDW), which is a specific marker of platelet activation, has been unclear in patients with heart failure (HF). METHODS AND RESULTS: We conducted a prospective observational study enrolling 1,746 hospitalized patients with HF. Patients were divided into tertiles based on levels of PDW: 1st (PDW < 15.9 fL, n = 586), 2nd (PDW 15.9-16.8 fL, n = 617), and 3rd (PDW ≥ 16.9, n = 543) tertiles. We compared baseline patients' characteristics and post-discharge prognosis: all-cause death; cardiac death; and cardiac events. The 3rd tertile showed the highest age and levels of B-type natriuretic peptide compared to other tertiles (1st, 2nd, and 3rd tertiles; age, 69.0, 68.0, and 70.0 years old, P = 0.038; B-type natriuretic peptide, 235.2, 171.9, and 241.0 pg/mL, P < 0.001). Left ventricular ejection fraction was equivalent among the tertiles. In the Kaplan-Meier analysis, rates of all endpoints were the highest in the 3rd tertile (log-rank P < 0.001, respectively). The Cox proportional hazard analysis revealed that the 3rd tertile was associated with adverse prognosis (all-cause death, hazard ratio [HR] 1.716, P < 0.001; cardiac death, HR 1.919, P < 0.001; cardiac event, HR 1.401, P = 0.002). CONCLUSIONS: High PDW is a novel predictor of adverse prognosis in patients with HF.
42
John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations
2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Journal of the American College of Cardiology · 2013 · 12.6K citations